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http://www.microbialcellfactories.com/content/12/1/121RESEARCH Open AccessGenetic dissection of the polyoxin building
block-carbamoylpolyoxamic acid biosynthesis
revealing the “pathway redundancy” in metabolic
networks
Wenqing Chen1,2,3,4, Daofeng Dai3, Changchun Wang1, Tingting Huang3, Lipeng Zhai3 and Zixin Deng1,3*Abstract
Background: Polyoxin, a peptidyl nucleoside antibiotic, consists of three building blocks including a nucleoside
skeleton, polyoximic acid (POIA), and carbamoylpolyoxamic acid (CPOAA), however, little is known about the
“pathway redundancy” of the metabolic networks directing the CPOAA biosynthesis in the cell factories of the
polyoxin producer.
Results: Here we report the genetic characterization of CPOAA biosynthesis with revealing a “pathway redundancy”
in metabolic networks. Independent mutation of the four genes (polL-N and polP) directly resulted in the
accumulation of polyoxin I, suggesting their positive roles for CPOAA biosynthesis. Moreover, the individual mutant
of polN and polP also partially retains polyoxin production, suggesting the existence of the alternative homologs
substituting their functional roles.
Conclusions: It is unveiled that argA and argB in L-arginine biosynthetic pathway contributed to the “pathway
redundancy”, more interestingly, argB in S. cacaoi is indispensible for both polyoxin production and L-arginine
biosynthesis. These data should provide an example for the research on the “pathway redundancy” in metabolic
networks, and lay a solid foundation for targeted enhancement of polyoxin production with synthetic biology
strategies.
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Nucleoside antibiotics, a family of important natural
products with microbial origin, have become research
focus in recent years for their diverse bioactivities and
promising application potentials [1,2]; usually, this family
of antibiotics harbors intricate structural features by
modification of nucleosides or nucleotides [2]. Polyoxins
(Figure 1A), a group of structurally-related nucleoside
antibiotics produced by Streptomyces cacaoi var. asoensis (S.
cacaoi hereafter) [3-5] and Streptomyces aureochromogenes* Correspondence: zxdeng@whu.edu.cn
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stated.[6], exhibit potent bioactivity against phytopathoengenic
fungi [2,7]. As the first nucleoside antibiotic targeting fungal
cell wall biosynthesis, polyoxin displays similar structural
features to that of UDP-N-acetylglucosamine, a substrate
for chitin biosynthesis, and thus it functions as a powerful
competitive inhibitor of chitin synthetase [7,8].
The structure of polyoxin is composed of three build-
ing blocks including a nucleoside skeleton, polyoximic
acid (POIA) and carbamoylpolyoxamic acid. Previous
studies with feeding experiments have demonstrated that
the three building blocks were individually originated
from uridine (or UMP), L-isoleucine and L-glutamate
[2]. Previously, the polyoxin biosynthetic gene cluster
was cloned and well characterized, and the entire poly-
oxin gene cluster was revealed to consist of 20 genes
(Figure 1B), of them, three genes (polF, polC and polE)td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 The proposed CPOAA biosynthetic pathway (A) and Genetic organization of the polyoxin biosynthetic gene cluster (B). The
initial two steps involved in CPOAA biosynthesis are overlapped with those of L-Arginine pathway.
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five genes (polL-P) were assigned as the roles for CPOAA
biosynthesis [9,10].
As proposed in previous studies, CPOAA is formed by
first transfer of an N-acetyl group to L-glutamate by
PolN to form N-acetyl-L-glutamate, followed by phos-
phorylation to form N-acetyl-L-glutamate phosphate by
PolP before stepwise reduction, deacylation, transcarba-
moylation and hydroxylation (Figure 1A) [9]. Remarkably,
the role of PolO as carbamoyltransferase catalyzing α-
amino-δ-hydroxyvaleric acid (AHV) to generate α-amino-
δ-hydroxyvaleric carbamoylhydroxyvaleric acid (ACV)
was unambiguously demonstrated by in vivo and in vitro
experiments [9]. According to the proposed pathway, the
first two steps were identical to those for the L-arginine
biosynthetic pathway, in which the initial steps involve
catalyzing L-glutamate to form N-acetyl-L-glutamyl-5-
phosphate by sequential acylation and phosphoralation
[9,11]. As an important amino acid, L-arginine plays key
roles in many metabolic pathways, either primary or sec-
ondary [11]. The L-arginine biosynthetic pathway was dis-
tinctly characterized in bacteria including E. coli andStreptomyces [11]. In E. coli, there is a linear biosynthetic
pathway for L-arginine biosynthesis [11], however, many
other bacteria such as Streptomyces harbor cyclic L-
arginine biosynthetic pathway [11-13], in which the
N-acyl group of the intermediate N-acetyl-L-ornithine
could be recycled as substrate for ArgA, therefore, the
protein, ArgJ, in Streptomyces displays bifunctional roles
for the acylation and deacylation [11].
Here we describe the genetic characterization of
CPOAA biosynthesis with unveiling of the “pathway re-
dundancy” in metabolic networks. In silico and genetic
analysis of the polyoxin gene cluster demonstrated that
five genes (polL-P) were involved in CPOAA biosyn-
thesis; moreover, the inter-connections between me-
tabolic pathways of polyoxin and L-arginine were
systematically characterized by in vivo genetic experi-
ments. All these will set the stage for the understanding
of the “pathway redundancy” in metabolic networks,
and pave the way for rational designing and optimizing
the polyoxin biosynthetic pathway so as to increase
antibiotic production via the strategies of pathway
engineering.
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In silico analysis of the candidate genes for CPOAA
biosynthesis
In silico analysis shows that the five genes (polL-P) in
the pol cluster seem to be involved in biosynthesis of
CPOAA. Among them, polL encodes a protein exhibiting
no detectable homology to any proteins in the database,
suggesting its obscure and unique catalytic mechanism for
CPOAA biosynthesis; PolM is a 255-aa protein with con-
siderable homology to short-chain dehydrogenase of
Pseudomonas aeruginosa PAO1. Short-chain dehydrogen-
ase is a very large family of enzymes, most of which are
known to be NAD- or NADP-dependent oxidoreductases.
The protein PolN shows low homology (32% identity) to
amino-acid N-acetyltransferase of Neisseria mucosa ATCC
25996. PolP exhibits 54% identity to the acetylglutamate
kinase of Frankia alni ACN14a, implying the similar cata-
lytic mechanism of PolP in CPOAA biosynthesis. PolO
displays significant homology to NodU, a carbamoyltrans-
ferase of Sinorhizobium sp [14], whose function was un-
ambiguously confirmed as a carbamoyl transferase by
previous in vitro experiments [9].Figure 2 Heterologous expression of the pJTU4620 derivatives (with
Schematic representation for the construction of pJTU4620 derivatives, the
Bioassay for the related S. lividans TK24 recombinants, the sample of pJTU4
and pJTU4620/ΔpolL were correspondingly spotted as 1-4; TK24 containing
the metabolites individually produced by the S. lividans TK24 recombinants
containing pJTU620 (4620) were used as positive controls, and TK24 contai
bearing 4620 derivatives were individually indicated as 4620/ΔpolN, pJTU46Independent mutation of polL-N led to the accumulation
of thymine polyoxin I
To demonstrate if polL-N play essential roles for CPOAA
biosynthesis, all three genes were directly in-frame deleted
in pJTU4620; after validation by PCR (Additional file 1:
Figure S1), the resultant pJTU4620/ΔpolL, pJTU4620/
ΔpolM and pJTU4620/ΔpolN cosmids (Figure 2A) were
independently introduced into S. lividans TK24 for heter-
ologous expression. Subsequently, the TK24 recombinants
were fermented at 30°C for 3 d. After that, the broth was
purified for bioassay and LC/MS analysis. Results shows
that the broth of both TK24 recombinants individually
containing pJTU4620/ΔpolL and pJTU4620/ΔpolM has
lost bioactivity against the indicator fungi, Trichosporon
cutaneum (Figure 2B), while the TK24 recombinant bear-
ing pJTU4620/ΔpolN was found to possess decreased bio-
activity against Trichosporon cutaneum in comparison
with the TK24 harboring intact pJTU4620 (Figure 2B).
Further HPLC analysis indicated the three TK24 recom-
binants obtained the ability to make a novel intermedi-
ate with abolishment/decreased polyoxin H production
(Figure 2C). For the identification of the novel intermediate,individual mutation of polN, polM and polL) in S. lividans TK24. (A)
genes polL-N were independently in-frame-deleted in pJTU4620. (B)
620 (TK24 containing pJTU4620), pJTU4620/ΔpolN, pJTU4620/ΔpolM
pSET152 (spot 5) was used as negative control. (C) HPLC analysis of
. The authentic polyoxin standards (ST) and the sample of TK24
ning pSET252 was used as negative control. The samples of TK24
20/ΔpolM and 4620/ΔpolL. POL: polyoxin.
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showed that the intermediate generates [M+H]+ ion at m/
z = 411.1 (Additional file 1: Figure S2), which was further
fragmented into distinctive ions of ca. 285.0, 267.0, 183.0,
and etc. (Additional file 1: Figure S2 and Figure S4), con-
sistent with those generated by thymine polyoxin I au-
thentic standard (Additional file 1: Figure S4); all the data
suggesting that polL-N are responsible for CPOAA bio-
synthesis, simultaneously, implicating that a homologous
gene is existed within the genome of S. lividans TK24 par-
tially complementing polN mutant to restore polyoxin H
production.
polN possesses the ability to restore the growth
phenotype for E. coli argA mutant
To get direct genetic evidence that polN functions as N-
acetylglutamate synthase (ArgA), E. coli thyA mutant (CH2)
was first constructed, validated by PCR (Additional file 1:
Figure S3), and plate grown experiments showed that theFigure 3 Targeted inactivation of argA in E. coli and mutant complem
CH3 mutant. (B) Identification of CH2 mutants. As 1.1-kb argA fragment wa
was ca. 1.5-kb, while the wild type produces 1.6-kb PCR product. (C) Comp
(1) and CH3 mutant containing pET28a (2) were used as negative controls,
indicated as (3). The final concentration for arginine and thymidine used in
liquid cultures were incubated at 37°C for 90 h.thyA (thymidylate synthase gene) mutant abolishes growth
phenotype without exogenous thymidine, demonstrating
the correct thyA-phenotype of CH2 mutant (Additional
file 1: Figure S3). CH3 mutant was further constructed on
the basis of CH2 mutant using thyA as anti-selective
marker [15]. PCR results showed that the CH2 mutant
could produce 1.6-kb product, while that of the candidate
CH3 mutants was 1.5-kb (Figure 3A, B). To investigate
whether polN could complement CH3 mutant, pJTU2838
bearing polN was introduced into the mutant CH3, and
complementation experiments indicated that polN har-
bors the ability to restore the growth phenotype for CH3
mutant, moreover, when grown in M9 liquid medium for
90 h, the OD600 of the complemented strain is 2.065, while
the negative controls (CH3 and CH3/pET28a) almost
stand still compared with the initial growth status
(Figure 3C, Additional file 1: Table S3); all these strongly
suggesting that polN is capable of cross-complementing
with argA in L-arginine biosynthetic pathway.entation by polN. (A) Representational map for construction of the
s replaced by 1.0-kb aac(3)IV gene, the PCR product for CH3 mutants
lementation of CH3 mutant by polN. CH3 mutant of E. coli BL21(DE3)
while CH3 mutant containing pJTU2838 with inserted polN was
this experiment is 50 μg/ml and 200 μg/ml, respectively, and the
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production
To demonstrate the positive role of polP involved in
CPOAA biosynthesis, the polP disruption vector,
pJTU2846, was conjugated into S. cacaoi, after valid-
ation, the conjugants were released on MS medium for
7 d, subsequently, the spores were diluted with gradient
on AprR MS medium, and random AprRThioS candidate
mutants were selected for further PCR confirmation.
Results shows that the wild type of S. cacaoi generates
1.0-kb product, and the PCR product of the two candi-
date polP mutants (CY7) is 1.6-kb in size (Figure 4B),
indicating that polP was successfully disrupted. For de-
tection of resultant phenotype of CY7, the two mutant
strains were cultivated for fermentation at 30°C for 3 d;
after that, the broth was further analyzed by bioassay
and HPLC. Compared with wild type of S. cacaoi, the
CY7 samples shows apparently decreased bioactivity
against the indicator fungi (Figure 4C), and HPLC ana-
lysis displayed that CY7 mutants partially lost the ability
to produce polyoxin (bioactive components against the
indicator fungi), meanwhile, the CY7 mutants also accu-
mulate two novel intermediates designated as N1 and
N2 (Figure 4C).Figure 4 Targeted inactivation of polP. (A) Schematic representation for
mutants, as a 1.1-kb aac(3)IV fragment replaced 495-bp of polP, the CY7 mu
product. (C) Bioassay of the metabolites produced by CY7 mutant, the sam
and the samples from CY7 mutants were indicated as (2-4). 35 μl sample (s
of the metabolites produced by CY7 mutant. Polyoxins authentic standard
control, and the sample from CY7 mutant was indicated as CY7.To further confirm the identities of the two intermedi-
ates (N1 and N2), both peaks were analyzed by LC/MS,
and the results showed that the peaks at 33.1 min and
36.5 min could produce the [M+H]+ ions at m/z = 427.3
and 411.4, respectively, which corresponds to the au-
thentic standards of polyoxin I and thymine polyoxin I
(Additional file 1: Figure S4), moreover, MS/MS frag-
mentation pattern of the two peaks were in consistent
with the standards (Additional file 1: Figure S4), suggest-
ing that polP is not essential for CPOAA biosynthesis
but only for its maximal production, likewise, indicating
a homolog existing to rescue the polP mutation.
polP is capable of complementing argB mutant of
Streptomyces coelicolor
To deduce whether polP could cross-complement with
its homolog, ArgB (N-acetyl glutamate kinase), the argB
gene in S. cacaoi was cloned (Additional file 1, HQ202571)
and sequenced as positive control for this study. Bioinfor-
matic analysis showed that ArgB of S. cacaoi exhibit 95%
identity to that of Streptomyces pristinaespiralis. For deep
investigation of in vivo function of polP, the argB in frame
deletion construct pJTU4710 was conjugated into S. coeli-
color, then the argB mutant (CX2) was screened accordingthe construction of CY7 mutant. (B) PCR confirmation of the CY7
tants give 1.6-kb PCR product, while WT of S. cacaoi produces 1.0-kb
ple of S. cacaoi wild type indicated as (1) was used as positive control,
upernatant) was used for all bioassays in this study. (D) HPLC analysis
(ST) and sample from wild-type of S. cacaoi (WT) were used as positive
Chen et al. Microbial Cell Factories 2013, 12:121 Page 6 of 11
http://www.microbialcellfactories.com/content/12/1/121to the standard protocols (Figure 5A) [16]. As confirmed
by PCR, the CX2 mutants give 0.68-kb product, where-
as that of the wild type of S. coelicolor is 1.1-kb in size
(Figure 5B). To see if pJTU2870 (polP) could complement
the CX2 mutant to restore growth phenotype; the vector
was introduced into CX2 for complementation. As Figure 5C
showed, polP could entirely complement argB mutant of
S. coelicolor (CX2) (Figure 5C), while the negative controls
(CX2 and CX2/pJTU2170) display the lethal phenotype
without exogenous L-arginine. Additionally, pJTU2838
(polP) was used to complement argB mutant of E. coli,
and results show that polP complemented strain harbors
the similar growth status to that complemented by argB
(S. cacaoi) (Additional file 1: Table S4 and Figure S5), all
the data suggesting that polP harbors identical in vivo
functions to argB, and further establishing that there is a
robust “cross-complementation” between them.
Natural argB plays essential roles for both polyoxin
production and L-arginine biosynthesis in S. cacaoi
To investigate whether argB mutant of S. cacaoi could
survive the growth environment without exogenous L-
arginine, the mutant (CY21) was constructed (AdditionalFigure 5 In frame deletion of argB in S. coelicolor A3(2) and mutant c
construction of CX2 mutant; B. PCR identification of CX2 mutant. As ca. 0.4
gives a 1.1-kb product, and the products of CX2 mutant are 0.68-kb in size
strains, S. coelicolor A3(2) wild type (1) and CX2 mutant complemented by
CX2 mutant containing empty vector, pJTU2170, was used as negative con
pJTU2870 (4) were indicated as parallels.file 1: Figure S6). In contrast with our expectations, the
CY21 mutants were unable to grow without added L-
arginine (Additional file 1: Figure S6). Furthermore, the
growth phenotype was entirely complemented by an intro-
duced argB (CY21/pJTU4713) (Additional file 1: Figure S6),
suggesting that the natural polP is not capable of comple-
menting the CY21 mutant, simultaneously excluding the
possibility of a polar effect (or frameshift mutation).
To further investigate into the interesting and unex-
pected phenotypes, argB and polP double mutant (CY22)
was constructed using CY21 as starter strain according to
the standard protocols [16], as PCR results showed that
the CY21 mutant is able to give 1.0-kb product, and the
product of CY22 mutant is 1.6-kb in size (Figure 6A).
Plate growth experiments indicated that CY22 mutant has
completely lost growth phenotype without exogenous L-
arginine (Figure 6B), while polP (pJTU2870) and argB
(pJTU4713) complemented strains were found to restore
growth phenotype, and the negative control CY22/
pJTU2170 displays lethal phenotype if no exogenous L-
arginine added (Figure 6B), in full consistence with the
expectations, thus suggesting that polP and argB share
the same in vivo function to restore growth phenotype
for the CY22 mutant.omplementation by polP. A. Schematic representation for
-kb of argB was in frame deleted, the wild type of S. coelicolor A3(2)
. C. Plate grown experiments for CX2 mutant and its complemented
argB (S. cacaoi) in pJTU4713 (5) were used as positive controls, and
trol (3); CX2 mutant (2) and its complemented strain by polP in
Figure 6 Natural argB plays essential roles for both polyoxin production and L-arginine biosynthesis. (A) PCR identification of CY22
mutant, the construction process is identical to that of CY7 mutant except that the CY21 mutant was used as start strain, and PCR product of
CY22 mutant (1) was compared with that of CY21 mutant (2). (B) Growth phenotype of CY22 and its related complemented strains in minimal
medium. CY7 mutant was used as positive control (1), and CY22 mutant (2) as well as its complemented strain (CY22/pJTU2170) with an empty
vector (3) were selected as negative controls, CY22/pJTU4713 (argB) (4) and CY22/pJTU2870 (polP) (5) were detected as parallels. (C) Bioassay for
the metabolites produced by CY22 and its related complemented strains. Samples of CY21 mutant (1), CY22 mutant (2), and CY22/pJTU2170 (3)
were detected in parallel with those of CY22/pJTU4713 (argB) (4) and CY22/pJTU2870 (polP) (5). (D) HPLC analysis of the metabolites produced by
the CY22 mutant and its related strains. Polyoxin authentic standard (ST) and metabolites produced by S. cacaoi wild type (WT) were used as
positive controls, while the metabolites produced by CY21, CY22, CY22/pJTU2170 were utilized as negative controls; the samples of CY22/argB
(pJTU4713) and CY22/polP (pJTU2870) were detected as parallels.
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by argB, the CY22 mutant and its complemented strains
were inoculated for fermentations, after that, the prepro-
cessed broth were subjected to bioassay analysis, and the
results showed that the samples of CY22 and CY22/
pJU2170 have abolished bioactivity against the indicator
strain, Trichosporon cutaneum (Figure 6C). More inter-
estingly and unexpectedly, the sample of the CY21 mu-
tant has also been deprived of the bioactivity against the
indicator strain, however, the CY22 mutant correspond-
ingly complemented by polP and argB regained the bio-
activity (Figure 6C). Further HPLC analysis indicated
that the samples of CY21, CY22 and CY22/pJTU2170
were not capable of producing the distinctive peaks of
either polyoxin A or polyoxin H as indicated by the
standards at 34.8 min and 40.9 min, respectively, while
the polP or argB complemented strains restored the abil-
ities to produce the characteristic peaks at correspond-
ing positions (Figure 6D).For further accounting for the phenotype of CY21 mu-
tant, the time-course transcriptional analysis and bioassay
of the WT and CY21 strains of S. cacaoi were performed,
and it is revealed that the transcription of the pol genes in
CY21 was significantly affected (Figure 7A, B), which dir-
ectly result in the abolishment of polyoxin production for
CY21 strain, all these strongly suggesting that polP could
cross-complement with argB, and revealing that argB
plays essential role not only for L-arginine biosynthesis
but also for polyoxin production.
Discussion
Nucleoside antibiotics are a family of secondary metabo-
lites whose biosynthetic precursors are originated from pri-
mary metabolisms including nucleotide (nucleoside),
amino acids and saccharides [1,2,17]. Previous experiments
assigned the biosynthetic precursors for the three building
blocks (nucleoside skeleton, POIA and CPOAA) of poly-
oxin as UMP, L-isoleucine and L-glutamate, respectively
Figure 7 Time-course bioassay and transcriptional analysis of S.
cacaoi CY21 strain (argB mutant). (A) Time-course bioassay for
CY21 and WT strains of S. cacaoi; (B) Time-course transcriptional ana-
lysis of S.cacaoi CY21 strain, and RT-PCR was used for time-course
transcriptional analysis of CY21 strain. “W” indicates wild type of S.
cacaoi, and “M” means CY21 mutant of S. cacaoi. The methods for
the time-course bioassay and time-course transcriptional analysis of
S. cacaoi CY21 strain were described in Additional file 1.
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beling results led to a proposal that the biosynthesis was
initiated by catalyzing L-glutamate to produce L-glutamate-
γ-semialdehyde, which was finally converted to CPOAA
with stepwise reactions [19,21].
The polyoxin biosynthetic gene cluster was previously
cloned and sequenced [9], and further bioinformatic in-
sights into the polyoxin biosynthetic gene cluster contra-
dict to the previously-deduced pathway. For one thing, the
hypothetic L-glutamate-γ-semialdehyde in CPOAA bio-
synthetic pathway was also a confirmed intermediate for
L-proline biosynthesis, and its automatic self-cyclization
would significantly decrease the efficiency for CPOAA
biosynthesis, moreover, the roles of PolN and PolP could
not be appropriately assigned in the CPOAA biosynthetic
pathway [9]. On the other hand, PolN pertains to GCN5
super family acetyl transferase, which is capable of utiliz-
ing broadly flexible substrate as acetyl group acceptor
[22]. PolP function is easier to be determined for itssignificant homology to ArgB, a well characterized protein
in L-arginine biosynthetic pathway [11,13]. Accordingly, it
was tentatively proposed that L-glutamate was catalyzed
by PolN to give rise to N-acetylglutamate, which was then
converted to N-acetylglutamate 5-phosphate in the charge
of PolP.
The existence of the demonstrated “pathway redun-
dancy” between the biosynthetic pathways of polyoxin
and L-arginine promoted us to ponder the interesting
phenomena raised in this study. Since the roles of polN
and polP were overlapped with those of argA and argB
in L-arginine biosynthesis, it seemed as if PolN and PolP
would be redundant and dispensable for polyoxin bio-
synthesis. However, microbial cells, more specifically, the
polyoxin producer, have chronically evolved, and their
cell factories should be highly efficient and economical
[23]. In this respect, the existence of polN and polP
seemed to be reasonable and necessary.
For microbial cells, L-arginine could be synthesized
via its biosynthetic pathway; nevertheless, the biosyn-
thesis would be partly decreased once the cells could de-
tect the existence of L-arginine [11,24]. Put it another
way, the switch for L-arginine biosynthesis was not in
full turn-on status for microbial cells with consistence of
exogenous L-arginine, from the point of view, polN and
polP were indispensible for polyoxin biosynthesis. Con-
sequently, mutants of polN or polP were only harbor
partial capability of polyoxin production. Another inter-
esting and unexpected phenomenon is the argB muta-
tion in S. cacaoi could not be complemented by natural
polP, and further research reveals argB plays essential
role for both biosynthesis of polyoxin and L-arginine,
namely, argB mutant simultaneously abolishes the phe-
notypes of growth and polyoxin production, partly ad-
dressing the interesting phenotype of CY21. For CY21
mutant, Mutation of argB means the L-arginine biosyn-
thetic pathway was interrupted, with the circumstance
occurred, the microbial cells would generate chain strin-
gent responses to turn off unessential secondary metab-
olisms, such as polyoxin biosynthesis. The unusual and
unexpected phenotypes found in this study promote us
to explore the precise molecular mechanisms for the im-
pact of L-arginine biosynthesis on regulation of polyoxin
production, and the related research is now in progress.
“Pathway redundancy” in metabolic networks was
widely distributed in nature, as the representative cases
characterized in the biosynthetic pathways of FR008/
candicidin [25] and clavulanic acid [26]. Indeed, the
interconnection between different pathways including
those of polyoxin and L-arginine suggests that the re-
lated proteins should be predominantly responsible for
their individual business in the metabolic networks; as a
result, “Cross-complementation” should be merely a
part-time job.
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Five genes (polL-P) in the current research were identi-
fied to be involved in CPOAA biosynthesis, and argA
and argB in L-arginine biosynthetic pathway contributed
to the “cross-complementation” with CPOAA pathway,
most interestingly, we found that argB in S. cacaoi is
indispensible for both polyoxin production and L-
arginine biosynthesis. These data should provide a case
for the research on the “pathway redundancy” in meta-
bolic networks, and lay a solid foundation for target im-
provement of polyoxin production via synthetic biology
strategy.
Materials and Methods
Bacterial strains and plasmids (cosmids)
Bacterial strains and plasmids (cosmids) used in this
research are described in Additional file 1: Table S1.
General methods and culture conditions
General approaches for the manipulation of E. coli and
Streptomyces were based on the standard methods of
Sambrook et al. [27] or Kieser et al. [16]. Strepmyces
were grown on MS agar or in TSB (YEME) liquid
medium at 30°C [16]. Liquid fermentation medium (per
liter containing: Soy powder 20 g, corn powder 20 g, sol-
uble starch 20 g, glucose 10 g, Yeast extract 10 g, CaCO3
4 g, K2HPO4 2 g, NaNO3 2 g, add tap water till 1 liter)
was used for polyoxin production. The MM agar [16]
and M9 medium [25] were used for detection of growth
phenotype for the arg mutant of E. coli or Streptomyces.
The final antibiotic concentration used in this study is
as follows: ampicillin 100 μg/ml, apramycin 30 μg/ml,
kanamycin 50 μg/ml, chloramphenicol 25 μg/ml and
thiostrepton 12.5 μg/ml.
DNA sequencing and sequence analysis
DNA sequencing was accomplished at Shanghai Maojor
Ltd using Applied Biosystems Model 3730 automated
DNA sequencer. Sequence data analysis was performed
with the FramePlot online program (http://watson.nih.go.
jp/~jun/cgi-bin/frameplot-3.0b.pl) [28]. Sequence homology
searches were performed using the NCBI online BLAST
software [29].
Construction of pJTU4620 for mutational analysis of the
target pol genes
For construction of pJTU4620, m5A7 cosmid [9] (contain-
ing XbaI and SpeI sites correspondingly located at the
both sides of foreign insertion) was initially digested by
XbaI, and the resultant cohesive ends were blunted by
Klenow Fragment (Fermentas). After that, the blunted
linear fragment was self-ligated to render pJTU4619, in
which SpeI site was subsequently blocked to generate
pJTU4620 with the method described as above.Independent mutation of polL-polN in pJTU4620 cosmid
For individual mutation of polL-polN in pJTU4620,
PCR-targeting technology was performed, and the neo
cassettes amplified by different pairs of the primers as
described in Additional file 1: Table S2 were independ-
ently recombined into pJTU4620 to result in mutation
of the target genes, subsequently, the neo cassette was
removed from pJTU4620 by XbaI-SpeI double digestion
leaving the in frame deletion scar.
Construction and complementation of E.coli argA mutant
(thyA and argA double mutant)
For construction of the argA mutant of E. coli, a 3.0-kb
fragment containing thyA of E. coli was cloned into
pKD46 [30] as negative selective marker, and CH2
(thyA-) mutant (Additional file 1: Figure S2) was used as
starter strain, with primers eargAF1 & eargAR1 and ear-
gAF2 & eargAR2-2, the double arms for argA disruption
were independently cloned into pIJ2925 to give pJTU2835,
then the EcoRI engineered double arms was cloned into
pJTU2183 to give pJTU2836, finally, the aac(3)IV from
pJTU2848 was inserted into the KpnI site of pJTU2836 to
generate the argA disruption vector, pJTU2847. For the
complementation of argA, an EcoRI-NdeI polN fragment
from pJTU2930 was cloned into identical sites of pET28a
to produce pJTU2838.
Construction and identification of CY7 mutant
For construction of the CY7 mutant, two polP disruption
arms were independently amplified with primers (H1L-
armF with H1L-armR and H1R-armF with H1R-armR)
and cloned in pBlueScriptII SK(+) to form pJTU2814 and
pJTU2815, respectively; and then a XbaI-PstI engineered
fragment from pJTU2814 was cloned into counterpart
sites of pJTU2815 to produce pJTU2816, and the PstI
engineered aac(3)IV fragment from pJTU2844 was cloned
into pJTU2816 to result in pJTU2845, from which the
XbaI-EcoRI engineered fragment was cloned into pHL212
(Tao et al., unpublished) to give the polP disruption vector,
pJTU2846. For identification of CY7 mutant, primers
H1DIR and H1DIF were used.
Construction, identification and complementation of
CY21 and CY22 mutants
For construction of the CY21 mutant, a BglII engineered
PCR fragment (primers caargBRf2 and caargBRR) was
cloned into BglII-HpaI sites of pOJ446 to generate
pJTU4730, and a BglII-XbaI PCR fragment (primers
caargB1f and caargBLR2) was inserted into corresponding
sites of pJTU4730 to result in pJTU4731. After that, a
BglII fragment bearing tsr was cloned into counterpart site
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caargBef and aegDR was used to identify CY21 mutants.
For construction CY22 mutant, polP was further disrupted
using CY21 as start strain according to the method de-
scribed as above. For the complementation of CY21
and CY22, polP and argB were individually cloned into
pJTU2170 to form pJTU2870 and pJTU4713.Construction and complementation of the argB mutant of
S. coelicolor A3(2) (CX2)
For construction of the CX2 mutant, the left arm for argB
mutation was amplified by KOD-plus (Toyobo) polymerase
with primers M145argBLF and M145argBLR, after treated
by XbaI, the fragment was cloned into XbaI-EcoRV sites of
pOJ260 to give pJTU4709, then the EcoRI-BamHI right
arm PCR product amplified with primer M145argBRF
M145argBRR was cloned into corresponding sites of
pJTU4709 to generate the argB in frame deletion vector,
pJTU4710. After that, this vector was conjugated into S.
coelicolor A3(2) for construction of argB in frame dele-
tion mutant (CX2) based on the standard protocols
[16]. For complementation of argB mutant of S. coelico-
lor, NdeI-EcoRI fragments containing polP (pJTU2829)
and argB (pJTU2883) was individually inserted into
pJTU2170 to generate pJTU2870 and pJTU4713.Purification and assay of polyoxin
Polyoxin produced by S. lividans TK24, S. cacaoi as well
as its derivatives was detected by bioassay and LC/MS
with Agilent 1100 series LC/MSD Trap system. For the
bioassay, Trichosporon cutaneum was used as indicator
strain, and the protocol were according to Chen et al.
[9]. For the purification and HPLC analysis of polyoxin,
the methods were based on Chen at al [9], and the tar-
geted fraction was collected and condensed before LC/MS
analysis.Conditions for LC/MS analysis
The conditions performed for LC/MS analysis were as
follows: Agilent ZORBAX SB-C18 column (4.6 × 250 mm),
flow rate 0.3 ml/min at room temperature with elution
gradient 5%-40% Methanol: 0.3% TFA (HPLC grade) over
40 min at 0.3 ml/min [31]. The elution was monitored at
262 nm with a DAD detector and the data were analyzed
with Agilent data analysis software.Accession number
The nucleotide and protein sequences reported in this
paper have been deposited in GenBank under the acces-
sion number HQ202571.Additional file
Additional file 1: Table S1. Strains, plasmids and cosmids used in this
study. Table S2: PCR primers used in this study. Table S3: Growth status for
CH3 mutant and its complemented strains. Table S4: Growth status for CH4
mutant and its complemented strains. Figure S1: Identification of pJTU4620
derivatives by PCR. (A) Identification of pJTU620/ΔpolL. (B) Identification of
pJTU620/ΔpolM. (C) Identification of pJTU620/ΔpolN. Figure S2: MS analysis
of the metabolites produced by pJTU4620 derivatives. Figure S3:
Constrution of CH2 mutants and confirmation of its related biological
phenotype. (A). Representational map for the construction of CH2 mutant;
(B). Identification of CH2 mutants, M: 1 kb plus ladder, 1: E. coli BL21(DE3)
wild type, 2-5: E. coli BL21(DE3) CH2 mutants; (C). Confirmation of the bio-
logical phenotype of CH2 mutants, 1: E. coli BL21(DE3) Wild type; 2-5: E. coli
BL21(DE3) CH2 mutants. Figure S4: LC/MS analysis of the metabolites pro-
duced by CY7 mutant. ST/(Thymine) POL-I: (Thymine) POL-I authentic standard,
ST/N1(N2): Novel compounds N1(N2) produced by CY7 mutant. Figure S5:
Construction and Complementation of the CH4 Mutant. (A). Representa-
tional map for construction of CH4 mutants; (B). PCR identification of CH4
mutants, M: 1 kb plus ladder, 1: E .coli BL21(DE3) wild type, 2-3: CH4 mutants;
(C). Minimal broth grown experiments for CH4 mutant and its complemen-
ted strains, 1: CH4 mutant, 2: CH4/pET28a, 3: CH4/pJTU2837, 4: CH4/
pJTU2884, 5: E. coli BL21(DE3). Figure S6: Costruction and complementation
of CY21 mutant. (A). Representational map for construction of CY21 mu-
tants; (B). PCR identification of CY21, M: 1 kb plus ladder, 1: S. cacaoi WT, 2-4:
f S. cacaoi CY21 mutants; (C). Plate grown experiments for CY21 mutant and
its complemented strain, 1: CY21 mutant, 2: CY21 mutant containing
pJTU2170 as negative control, 3: CY21 mutant containing pJTU4713 (argB
gene inserted into pJTU2170), 4: S. cacaoi wild type.
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